Updated to include additional earnings reports, including CVS Health.
If you'd like to receive "5 Things" in your email inbox every morning, please register for TheStreet Alerts and follow me.
Here are five things you must know for Tuesday, Nov. 8:
1. -- Stock futures were lower on Tuesday as voters in the U.S. headed to the polls to elect the country's next president.
Stocks rebounded from a nine-day losing streak on Monday, posting the biggest gains in eight months, as confidence in an election win for Democratic presidental candidate Hillary Clinton over her Republican rival Donal Trump inspired market bulls.
Shares in Europe and Asia traded cautiously ahead of the U.S. election.
The economic calendar in the U.S. on Tuesday includes the Job Openings and Labor Turnover Survey for September at 10 a.m. EST.
2. -- U.S. state attorneys general have joined a federal antitrust probe of the planned merger between DuPont (DD) and Dow Chemical (DOW) , Reuters reported, citing three people familiar with the matter, while a separate group of state attorneys general are expected to join a probe of Bayer's $66 billion deal to buy Monsanto (MON) .
About seven states, including California, have joined the probe of Dow's planned merger with DuPont. It wasn't yet clear how many states would join the Bayer-Monsanto merger investigation, one source said.
The states are concerned that the companies may raise pesticide and herbicide prices for farmers following a merger, and have less incentive to compete to introduce better and cheaper products, two of the sources told Reuters.
DuPont and Dow said in separate statements they expected to gain approval for their deal. "In the U.S., we are working constructively with federal and state regulatory authorities, elected officials and all agriculture stakeholders to show the pro-competitive benefits of the merger," the companies said.
Committee chairman Sen. Charles Grassley (R., Iowa) and Sen. Patrick Leahy (D., Vt.) said in a letter to the FTC that the agency should look into issues including school contracts that restricted purchases of EpiPen competitors, The Wall Street Journal reported.
Mylan officials didn't immediately respond to requests for comment from the Journal on Monday.
Mylan has been heavily criticized for a more-than-sixfold price increase in the EpiPen since it bought the product in 2007.